Find Ophthalmology Clinical Drug Pipeline Developments & Deals

Lead Product(s): QR-421a

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of vision loss in Usher syndrome type 2 and non-syndromic retinitis pigmentosa.

Lead Product(s): Bevacizumab

Therapeutic Area: Ophthalmology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: BioLexis Pte. Ltd

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 28, 2020

Details:

Outlook Therapeutics signed agreement with BioLexis Pte. Ltd to better align the interests of all parties with common stockholders of the Company and to help ONS-5010's continuing development.

Lead Product(s): Triamcinolone Acetonide

Therapeutic Area: Ophthalmology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

The data demonstrated that patients with noninfectious uveitis in the XIPERE study arm experienced clinically significant improvement in vision relative to the control arm.

Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

Adverum Biotechnologies is conducting a phase1 study of Intravitreal gene therapy with ADVM-022 for Neovascular AMD (OPTIC Trial).

Lead Product(s): APX3330

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Ocuphire Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 22, 2020

Details:

Under the terms and conditions of the deal, Ocuphire earns an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330.

Lead Product(s): Dexamethasone

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

The Phase 2 trial data is the first controlled study of OCS-01 for the treatment of DME.

Lead Product(s): Reproxalap

Therapeutic Area: Ophthalmology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2020

Details:

The INVIGORATE Trial, which will enroll approximately 120 patients aims to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared with vehicle using an allergen chamber.

Lead Product(s): Sodium Hyaluronate

Therapeutic Area: Ophthalmology

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Bonus BioGroup

Deal Size: $7.4 million Upfront Cash: Undisclosed

Deal Type: Agreement January 16, 2020

Details:

This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.

Lead Product(s): NRO-1

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable